EUVIMEDEUVIMED entdecken
Crossref

SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B

Huiying Yu iD, Bin Li iD, Huili Guo iD, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Huiying Yu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, Hepatitis B virus, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional cure is the ideal treatment endpoint of chronic hepatitis B (CHB). Currently, only a few patients achieve this with treatment. Host differences must be influential. Solute carrier family 22 member 1 (SLC22A1), encoding organic cation transporter 1, is expressed in the liver and mediates substance transport of hepatocytes. The association between SLC22A1 and CHB has not been determined. Our objective was to elucidate this association.

Methods

RNA sequencing was performed to explore the changes caused by hepatitis B virus (HBV) and SLC22A1. Plasma from 200 patients with CHB (120 uncured, 80 cured) completing the pegylated interferon alpha (pegIFNα)–based treatment was collected at baseline and at 12 and 24 weeks of treatment. SLC22A1 of plasma and liver biopsies in healthy controls and patients with CHB were measured by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry.

Results

SLC22A1 was down-regulated by HBV, as indicated by comparing SLC22A1 of hepG2 cells with and without HBV and of both liver and plasma in CHB and healthy volunteers. Plasma SLC22A1 rose dynamically in the cured group but not in the uncured group. Plasma SLC22A1 at 24 weeks was predictive of functional cure (area under the receiver operating characteristic curve [AUC], 0.887) and better when combined with hepatitis B surface antigen (HBsAg) at 24 weeks (AUC, 0.925). In vitro experiments regarding overexpression of SLC22A1 in hepG2.2.15 demonstrated that HBsAg and hepatitis B e antigen were inhibited by SLC22A1 through JAK/STAT pathway activation, consistent with transcriptome sequencing results.

Conclusions

HBV inhibits SLC22A1 expression and SLC22A1 suppresses HBV by activating the JAK/STAT pathway. SLC22A1 is a predictor of the functional cure of CHB with pegIFNα-based treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicInterferon-alphaHepatitis B virusAntiviral AgentsJanus KinasesHumansMaleFemaleAdultMiddle AgedHep G2 CellsPolyethylene GlycolsLiverSignal Transduction

Stichwörter der Autor:innen

SLC22A1chronic hepatitis Bfunctional cureorganic cation transporter 1pegylated interferon-α

Substanzen

Interferon-alphaAntiviral AgentsPolyethylene GlycolsJanus Kinases

Autor:innen und Institutionen

  • Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
  • Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510062, China.
  • Department of Rheumatology and Immunology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510062, China.
  • Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

ORCID-Profile: Huiying Yu, Bin Li, Huili Guo

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Science and Technology Project

Zitieren

APA

Yu, H., Li, B., Guo, H., Li, L., Liu, X., Wu, L., Gao, N., Zhao, Q., Pang, X., & Gao, Z. (2025). SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf102

Vancouver

Yu H, Li B, Guo H, Li L, Liu X, Wu L, et al. SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf102

BibTeX
@article{Yu2025,
  author = {Yu, Huiying and Li, Bin and Guo, Huili and Li, Lin and Liu, Xiaoquan and Wu, Lili and Gao, Na and Zhao, Qiyi and Pang, Xiuqing and Gao, Zhiliang},
  title = {SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf102}
}
Kostenlos starten →